^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fosaprepitant

    i
    Other names: MK-0517, ONO-7847, L-785,298 , aprepitant prodrug
    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    NK-1 antagonist
    Related drugs:
    Associations

    News

    Trials
    1m
    QLM2010-301: To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. (clinicaltrials.gov)
    P3, N=665, Completed, Qilu Pharmaceutical Co., Ltd. | Recruiting --> Completed | Trial completion date: Mar 2026 --> Oct 2025 | Trial primary completion date: Dec 2025 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    dexamethasone injection • fosaprepitant
    2ms
    Prevention of Delayed CINV after Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen (ChiCTR2500110061)
    P3, N=92, Not yet recruiting, The affiliated people's hospital of Ningbo University; The affiliated people's hospital of Ningbo University
    New P3 trial
    |
    FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO)
    |
    dexamethasone • fosaprepitant • olanzapine
    3ms
    BARF RCT: Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide (clinicaltrials.gov)
    P4, N=212, Not yet recruiting, Montefiore Medical Center | Initiation date: Jun 2025 --> May 2026 | Trial primary completion date: Mar 2026 --> Feb 2027 | Phase classification: P2/3 --> P4 | Trial completion date: Mar 2026 --> Feb 2027
    Phase classification • Trial completion date • Trial initiation date • Trial primary completion date
    |
    fosaprepitant
    4ms
    Antiemetic Fosaprepitant To Remedy Nausea and Vomiting (clinicaltrials.gov)
    P2/3, N=250, Recruiting, Montefiore Medical Center | Trial completion date: May 2025 --> Jun 2026 | Trial primary completion date: May 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    fosaprepitant • ondansetron intravenous
    4ms
    Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting (clinicaltrials.gov)
    P3, N=126, Not yet recruiting, The First Affiliated Hospital of Xinxiang Medical College
    New P3 trial
    |
    megestrol • medroxyprogesterone • fosaprepitant • ondansetron
    5ms
    Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) (clinicaltrials.gov)
    P2, N=95, Recruiting, Helsinn Healthcare SA | Not yet recruiting --> Recruiting
    Enrollment open
    |
    fosaprepitant • ondansetron intravenous
    5ms
    QLM2010-301: To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. (clinicaltrials.gov)
    P3, N=664, Recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    dexamethasone injection • fosaprepitant
    7ms
    A prospective, single-arm clinical study of dolasetron mesylate injection in the prevention of nausea and vomiting caused by highly emetogenic chemotherapy (ChiCTR2500101930)
    P4, N=233, Not yet recruiting, Shao Yi Fu Hospital Affiliated to Zhejiang University School of Medicine; Shao Yi Fu Hospital Affiliated to Zhejiang University School of Medicine
    New P4 trial
    |
    anastrozole • dexamethasone • fosaprepitant
    9ms
    Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) (clinicaltrials.gov)
    P2, N=95, Not yet recruiting, Helsinn Healthcare SA
    New P2 trial
    |
    fosaprepitant • ondansetron intravenous
    9ms
    Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention (clinicaltrials.gov)
    P=N/A, N=144, Enrolling by invitation, Samsung Medical Center | Trial completion date: Mar 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    dexamethasone • fosaprepitant
    1year
    BARF RCT: Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide (clinicaltrials.gov)
    P2/3, N=212, Not yet recruiting, Montefiore Medical Center
    New P2/3 trial
    |
    fosaprepitant
    1year
    FONDO-LOW: Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan (clinicaltrials.gov)
    P3, N=172, Recruiting, Augusta University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dexamethasone • melphalan • fosaprepitant • olanzapine • ondansetron